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In chronic myeloid leukemia, the identification of individual BCR-ABL1 fusions is required for the development of
personalized medicine approach for minimal residual disease monitoring at the DNA level. Next generation sequencing
(NGS) of amplicons larger than 1000 bp simplified and accelerated a process of characterization of patient-specific
BCR-ABL1 genomic fusions. NGS of large regions upstream and downstream the individual breakpoints in BCR and
ABL1 genes, respectively, also provided information about the sequence variants such are single nucleotide
polymorphisms.
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BCR-ABL1 transcript level monitoring is a crucial part
of therapy response evaluation in patients with chronic
myeloid leukemia (CML). Molecular response (MR) in
CML is expressed in terms of log reduction in BCR-
ABL1 transcript levels from a standardized baseline on
an international scale [1]. An increasing number of
chronic phase CML patients treated with tyrosine kinase
inhibitors (TKIs) achieve sustained deep MR, which has
led to the initialization of TKI discontinuation studies
[2,3]. Although existing results showing that permanent
TKI discontinuation is feasible in a proportion of pa-
tients, more than half experience molecular relapse.
More sensitive MRD detection might allow to more
accurately stratifying patients according to the depth of
response, hence to the greater or smaller likelihood of
relapse after discontinuation. It was recently shown that
MRD could be detected at DNA level despite patients* Correspondence: katerina.machova@uhkt.cz
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unless otherwise stated.were in stable MR with undetectable BCR-ABL1 tran-
scripts [4,5]. It is supposed that quantification of BCR-
ABL1 gene would be useful for MRD monitoring in
patients with therapy cessation.
At the genomic level the BCR-ABL1 fusion is unique
to each CML patient, since breakpoints are scattered
within intron 13 (718 bp) or 14 (2128 bp) of BCR and
within intron 1 of ABL1 (140 Kbp). The exact genomic
sequence of the BCR-ABL1 fusion must therefore be
characterized to design a personalized real-time poly-
merase chain reaction (PCR) assay. The sensitivity of
personalized real-time PCR assay quantifying clone-
specific fusions was reported to be down to less than
10−5 (depending on the amount of DNA entering the
reaction) when nested PCR was used [6,7]. As amplifi-
cation of large regions (˃1 Kbp) is needed, the
characterization of BCR-ABL1 genomic fusions using
conventional sequencing has been a challenging task
[8-10]. With the aim to characterize patient-specific
BCR-ABL1 fusions, we set up a strategy based on thetral. This is an Open Access article distributed under the terms of the Creative
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Range PCR (mLR-PCR) and on subsequent ultra-wide
sequencing using NGS technology. NGS provided se-
quences of large regions upstream and downstream
the BCR-ABL1 fusions, allowing us to assess the fre-
quency of annotated single nucleotide polymorphisms
(SNPs), which could be associated with the fusion gene
formation.Findings
Next generation sequencing of large amplicons carrying
BCR-ABL1 fusions
The patient cohort consisted of 24 males and 22 females
with CML. Two BCR-ABL1 positive cell lines K562 and
JURL-MK were included as controls of BCR-ABL1 fusion
identification. Twelve healthy individuals were used as con-
trols for SNP detection in the BCR region from exon 13 to
exon 15.
DNA was isolated from total leukocytes of peripheral
blood at the time of diagnosis ensuring high amount of
BCR-ABL1 DNA present in the sample. Two-round mLR-
PCR was performed with HiFi Accuprime Taq DNA poly-
merase (Invitrogen) enabling amplification of large regions.
The amplification strategy is presented in Figure 1. In the
first round PCR with one primer in BCR exon 13 and 10
primers in ABL1 intron 1 [9], the long PCR products of 29
patients were obtained. In the second round PCR with one
primer in BCR exon 13 and 20 primers in ABL1 intron 1
[10-12] products were obtained in the remaining cases.
Median length of long PCR products was 5 Kbp (range
1-12 Kbp). Subsequently, rapid library was prepared for 454
NGS technology according to the manufacturer’s instruc-
tions and was run on a GS Junior instrument (Roche Diag-
nostics). NextGene software (Softgenetics) and referenceFigure 1 Schematic localization of primers. Forward primers hybridizing in
right and reverse primers spanning the intron 1 of gene ABL1 are symboliz
illustrate two-rounds of multiplex LR-PCR. LR-PCR products were obtained
color) localized in BCR exon 13 and 10 reverse primers (red color) spanning
remaining 23/48 cases from the second round PCR with 1 forward primer
primers (blue colors) hybridizing to ABL1 intron 1 [7,10].sequences NG_009244.1 (BCR) and NG_012034.1 (ABL1)
were used for sequence analysis.
Patient-specific BCR-ABL1 fusion characterization
Breakpoints in BCR were located in intron 13 in 8/46
patients, carrying the e13a2 mRNA fusion, and in intron
14 in 38/46 patients and in both cell lines, carrying the
e14a2 mRNA fusion (Figure 2A). All ABL1 breakpoints
were spread within intron 1 (Figure 2A), which is in ac-
cordance with a previous study [7]. Sequences of charac-
terized breakpoints are provided in the NCBI Nucleotide
database (Accession numbers – KR091980-KR092025).
SNPs detection upstream and downstream from the
BCR-ABL1 fusions
Downstream the individual breakpoints in ABL1, 56
annotated SNPs were detected in 15/46 patients (me-
dian 3 SNPs/patient, range 1–11). Only 10 of them
recurred in two patients, whereas the remaining 46
were detected only once. This heterogeneity in SNP
detection was caused by the extreme length of intron
1 (Figure 1, Figure 2A), where the breakpoints were
spread, so that the individual ABL1 regions sequenced
could not overlap.
Upstream the individual BCR breakpoints, 17 annotated
SNPs and 3 novel variants were found altogether in 27/48
cases (56%) (Figure 2B). The dbSNP assigned accessions of
newly detected variants (putative SNPs) are as follows:
NG_009244.1:g.114249A > G|rs527236141|ss1227131697;
NG_009244.1:g.114278G > T|rs527236142|ss1227132188;
NG_009244.1:g.115017 T > A|rs527236143|ss1227132282.
The 300 bp region downstream of primers hybridizing
to BCR exon 13 was sequenced in all cases (Figure 2B).exon 13 of the BCR gene are symbolized by arrows pointing to the
ed by arrows pointing to the left. Colors of arrows for each gene
in 25/48 cases from the first round PCR using 1 forward primer (red
the whole ABL1 intron 1 [9]. LR-PCR products were obtained in the
(blue color) hybridizing to sequence of BCR exon 13 and 20 reverse
Figure 2 A. Breakpoint traces in BCR intron 13 and intron 14 and in ABL1 intron 1. B. SNPs detected in individual BCR-ABL1 alleles upstream the
BCR breakpoints. Dots show detected SNPs; colors of dots correspond to each patient in whom SNPs were detected; colors of BCR breakpoints
indicate each patient in whom SNPs were detected; BCR breakpoints shown in black represent patients in whom SNPs were not detected; *novel
SNPs (numbers indicate position in ref. seq. NG_009244.1) **minor allele in a homozygous form; BCR region sequenced in all patients;
SNPs whose rs code is in red font are localized within this region. SNPs not detectable in patients because of their localization beyond the
breakpoints. Twelve healthy donor samples (controls) were used as controls for SNP detection in the BCR region from exon 13 to exon 15.
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9% of patients with e13a2 mRNA fusion and in 12% of
patients with e14a2 mRNA. Other 16 SNPs were detected
almost exclusively in patients with e14a2 mRNA fusion,
which is in accordance with the fact, that the BCR regionsequenced in these patients was larger than in the patients
with e13a2 mRNA. The minor allele frequency among the
BCR-ABL1 alleles analyzed corresponds to that found in
the 1000 GenomePhase Population and in the cohort,
although small, of healthy donors (Figure 2B).
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Although increasing number of studies has been pub-
lished in last few years [6-16], analysis of BCR-ABL1 at
the DNA level has been limited and difficult so far.
Our mLR-PCR-NGS approach streamlined the labora-
tory workflow for patient-specific BCR-ABL1 fusion
characterization allowing personalizing real-time PCR
assays for patients with MRD. The large collection of
46 BCR-ABL1 fusion sequences was obtained in the
short time and is at disposal in the NCBI Nucleotide
database. Moreover, the NGS enabled to detect SNPs
upstream and downstream the patient-specific break-
points of the BCR-ABL1 gene. NGS of this region in
large series of patients has the potential to provide
insights on the association between particular SNPs
or haplotypes and CML. Although we describe the
method on BCR-ABL1 in patients with CML, the strat-
egy can be used in the same manner as a base for
DNA-based MRD monitoring in BCR-ABL1 positive
acute lymphoblastic leukemia (ALL), where significant
differences between MRD levels measured by BCR-
ABL1 expression and Ig/TCR DNA-based approach
were described [17]. Moreover identical approach can
be used for breakpoints localization and sequence fea-
tures calling in other large fusion genes associated
with various cancers, e.g. TEL/ABL1 (atypical CML or
ALL) [18], TEL/AML1 (acute lymphoid leukemia) [19],
TMPRSS2/ERG (prostate cancer) [20] or EML4/ALK
(non-small cell lung cancer) [21].
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